Last update July 31, 2018
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Perindopril is also known as
Perindopril in other languages or writings:
Perindopril belongs to this group or family:
Main tradenames from several countries containing Perindopril in its composition:
|Oral Bioavail.||65 - 75||%|
|Protein Binding||10 - 20||%|
|Tmax||3 - 4||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Perindopril and its active metabolite perindoprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension and heart failure.
Oral administration every 12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts (Anderson 2018, Lwin 2017).
Until there is more information about this drug in relation to breastfeeding, safer known alternatives are preferable.
Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015).
The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).